NSEDCP
ADAP

NJ State Employees Deferred Compensation Plan’s Adaptimmune Therapeutics ADAP Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,000
Closed -$131K – 462
2017
Q3 		$131K Hold
16,000
– – 0.02% 445
2017
Q2 		$71K Hold
16,000
– – 0.01% 403
2017
Q1 		$89K Hold
16,000
– – 0.02% 381
2016
Q4 		$64K Hold
16,000
– – 0.01% 363
2016
Q3 		$112K Hold
16,000
– – 0.02% 354
2016
Q2 		$130K Hold
16,000
– – 0.03% 355
2016
Q1 		$151K Hold
16,000
– – 0.03% 357
2015
Q4 		$193K Hold
16,000
– – 0.04% 353
2015
Q3 		$192K Hold
16,000
– – 0.04% 347
2015
Q2 		$293K Buy
+16,000
New +$275K 0.06% 324

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's ADAP Position: Q4 2017 in Review

NJ State Employees Deferred Compensation Plan sold out of Adaptimmune Therapeutics (ADAP) in Q4 2017, closing a stake of 16,000 shares — an estimated $131K sold.

NJ State Employees Deferred Compensation Plan first reported a position in ADAP in Q2 2015 and held it in 10 quarters. The position peaked at $293K in Q2 2015. 71 funds tracked by Wall St. Rank hold ADAP as of Q4 2017.

  • NJ State Employees Deferred Compensation Plan reported no remaining Adaptimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • NJ State Employees Deferred Compensation Plan sold 16,000 Adaptimmune Therapeutics shares in Q4 2017, an estimated $131K.
  • NJ State Employees Deferred Compensation Plan first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 10 quarters.
  • NJ State Employees Deferred Compensation Plan's Adaptimmune Therapeutics position peaked at $293K in Q2 2015.
  • 71 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2017.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2017, filed 6 Feb 2018.